Abstract
Bone scintigraphy with technetium-99m (99mTc)-labeled diphosphonates is one of the most frequently performed radionuclide procedures. Accumulation of 99mTc-labeled diphosphonate is well recognized to reflect conditions of accelerated bone turnover and metabolism. Therefore, it is a functional imaging modality for detecting metastatic bone tumors, metabolic bone disease, traumatic injury, and inflammation. This pictorial essay describes the possible patterns of distribution of abnormal uptake for differential diagnosis of metastatic bone tumor, as well as the diagnostic pitfalls of bone scintigraphy.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Bone scintigraphy with Tc-99m labeled diphosphonates has been frequently used in searches for metastatic bone tumors. Recently, 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) for cancer staging or detection of recurrence has been covered by the health insurance in Japan; therefore, the number of bone scintigraphy procedures for evaluation of bone metastasis has been declining. On the other hand, bone scintigraphy is still often used to search for osteoblastic or mixed metastasis according to tissue-specific characteristics of the primary malignant tumor, such as prostate cancer and breast cancer. In general, the presence of multiple and randomly distributed foci of increased uptake of varying shapes is highly suggestive of metastatic bone tumor. Although multiple or diffuse increased uptakes may be encountered in metabolic bone disease, trauma, and inflammation, analysis of the pattern of distribution of the abnormalities can often distinguish metastatic disease from other entities [1]. Therefore, understanding the pattern of abnormal increased uptake on bone scintigraphy is recommended.
Metastatic disease
In general, abnormal increased uptake of bone lesions depends on the osteoblastic response, which is associated with bone destruction from the metastatic process [2]. Osteoblastic metastasis is most commonly found in patients with prostatic carcinoma (Fig. 1). Ovarian and gastric carcinoma may also give rise to osteoblastic bone metastasis, but at a lower frequency (Fig. 2). On occasion, extensive disease dissemination may be characterized by increased uptake throughout the entire skeleton, as well as faint uptake by the kidneys [3] (Fig. 3).
Results may be falsely negative in cases of aggressive metastases with insufficient osteoblastic response, intratrabecular metastases, or micrometastases. In such cases that have rapid destruction by the osteolytic process, bone scintigraphy would show “cold lesions” with absent uptake. A rim of increased uptake would indicate minimal osteoblastic reaction in the periphery (Fig. 4). These bone scintigraphy findings may become a diagnostic pitfall for osteolytic metastasis. Moreover, it is also difficult to reveal intratrabecular metastases and micrometastases on bone scintigraphy, since these metastatic lesions do not cause significant changes of trabecular bone [4].
Single photon emission computed tomography (SPECT) complements whole body imaging and may help detect additional bone lesions. It also provides three-dimensional anatomical information that can improve localization of abnormal uptakes [5]. For example, metastasis to the sacrum may be obscured by bladder activity and be missed on planar images. However, SPECT images can clearly reveal focal uptake in the sacrum (Fig. 5).
Metabolic disorders
Metabolic bone disorders are characterized by high bone turnover, which results in increased uptake of bone agents. Excessive parathyroid hormone is common in these conditions and the degree of abnormality on bone scintigraphy is directly related to the severity and duration of the disease [6].
Renal osteodystrophy (ROD)
ROD produces changes in bone metabolism due to chronic renal dysfunction. It combines features of secondary hyperparathyroidism, rickets, osteomalacia, and osteoporosis in varying degree. Bone scintigraphy has been acknowledged to be a sensitive method for early detection and assessment of ROD [7]. In patients with high-turnover ROD, uptake throughout the skeleton is markedly increased, especially in the calvaria, and the kidneys frequently appear faint [8] (Fig. 6).
Osteomalacia
Osteomalacia results from vitamin D deficiency, which produces profound mineralization defects. In severe cases, there is massive excess of osteoid and markedly reduced mineralization. On bone scintigraphy, abnormal increased uptake is most visible at the periarticular zones and costochondral junctions (Fig. 7a). The reason for increased uptake in osteomalacia is not well known, even if there is an underlying defect in mineralization [8]. Notably, pseudofractures are often detected in osteomalacia (Fig. 7b). Bone scintigraphy is a sensitive tool for identifying pseudofractures, whereas conventional radiology cannot detect these lesions. Furthermore, bone scintigraphy can be used to monitor response to treatment of these metabolic disorders (Fig. 7c).
Primary hyperparathyroidism
Primary hyperparathyroidism is a common disorder that involves increased secretion of parathyroid hormone, leading to hypophosphatemia and hypercalcemia. Bone scintigraphy may show uptakes that range in appearance from normal to that mimicking ROD. The presence of focal increased uptake in primary hyperparathyroidism is uncommon, but may be seen when brown tumors are present (Fig. 8). A brown tumor is characterized by high osteoclastic activity and bone resorption, and is most commonly found in the pelvis, ribs, skull, and jaw. Brown tumors may be misdiagnosed as malignant; therefore, giant cell tumor, fibrous dysplasia, aneurysmal bone cyst, and bone metastasis must be considered in its differential diagnoses [9].
Growth disorder
Fibrous dysplasia (FD)
FD is a benign skeletal developmental disorder of unknown etiology and is characterized by fibrous osseous metaplasia of the medullary bone [10]. It is most commonly of the monostotic type. On the other hand, polyostotic FD is asymmetrical and tends to be symptomatic earlier, with fractures and deformities in early childhood. Polyostotic FD that is associated with one or more extraskeletal conditions, such as café-au-lait skin pigmentation, sexual precocity, and other endocrinopathies, is known as McCune–Albright syndrome (Fig. 9). Bone scintigraphy demonstrates increased uptake in the involved sites. Search for such polyostotic involvement, which is often asymptomatic, is the main indication for bone scintigraphy [11].
Inflammation
Osteomyelitis
Osteomyelitis causes rapid osteoblastic response, which can be readily detected as inflammatory changes on bone scintigraphy (Fig. 10a). Changes can be expected to occur rapidly in the course of any bone and joint infection and bone scintigraphy is of paramount importance to help in early diagnosis. However, conditions associated with increased bone metabolism (e.g., tumors and trauma) may mimic osteomyelitis [12].
Because of diminished specificity of bone scintigraphy, complementary imaging with gallium citrate 67 (67Ga) scintigraphy is often performed [13] (Fig. 10b). 67Ga was reported to have faster uptake and to be more sensitive in detecting osteomyelitis than 99mTc-labeled diphosphonate. However, because of greater cost and radiation burden, 67Ga may be reserved for patients in whom there is a high clinical suspicion of osteomyelitis that cannot be clearly defined by bone scintigraphy.
Trauma
Changes from traumatic bone injury generally manifest as discrete focal uptakes of similar intensity [14]. Multifocal rib trauma has a characteristic linear or curved distribution of uptake (Fig. 11a). Metastasis to the rib tends to be elongated; on the other hand, a rib fracture tends to be round in shape (Fig. 11b, c).
Furthermore, in older patients, compression fractures and degenerative changes may manifest as areas of increased uptakes on bone scintigraphy. It has a useful role in evaluation of oncologic patients with back pain. Osteoporosis with advancing age has a high risk of fracture due to trauma. If a benign compression fracture is present, the classical bone scintigraphy finding of the fracture is a horizontal linear uptake at the fracture site [15] (Fig. 12a). The differentiation of benign compression fracture from bone metastasis is also important. However, interpreting increased abnormal uptake in the spine could be difficult, since a benign compression fracture or degenerative change may be indistinguishable from bone metastasis. Therefore, plain radiography, computed tomography, or magnetic resonance imaging are often required for additional findings (Fig. 12b).
Conclusions
We have shown the different multiple abnormal uptakes on bone scintigraphy for metastatic bone tumor, metabolic bone disease, trauma, and bone inflammation. We have described the possibilities and limitations of using the pattern of distribution of abnormal uptakes in the differential diagnoses of metastatic bone tumors. We have also shown findings that can be diagnostic pitfalls on bone scintigraphy.
References
Brenner AI, Koshy J, Morey J, Lin C, DiPoce J. The bone scan. Semin Nucl Med. 2012;42:11–26.
Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;15:1655–64.
Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro CJ. Radionuclide bone imaging: an illustrative review. Radiographics. 2003;23:341–58.
Yamaguchi T, Tamai K, Yamato M, Honma K, Ueda Y, Saotome K. Intertrabecular pattern of tumors metastatic to bone. Cancer. 1996;78:1388–94.
Murray IP, Dixon J. The role of single photon emission computed tomography in bone scintigraphy. Skelet Radiol. 1989;18:493–505.
Ryan PJ, Fogelman I. Bone scintigraphy in metabolic bone disease. Semin Nucl Med. 1997;27:291–305.
Fogelman I, Collier BD, Brown ML. Bone scintigraphy: part 3. Bone scanning in metabolic bone disease. J Nucl Med. 1993;34:2247–52.
Cook GJ, Gnanasegaran G, Chua S. Miscellaneous indications in bone scintigraphy: metabolic bone diseases and malignant bone tumors. Semin Nucl Med. 2010;40:52–61.
Meydan N, Barutca S, Guney E, Boylu S, Savk O, Culhaci N, et al. Brown tumors mimicking bone metastases. J Natl Med Assoc. 2006;98:950–3.
Collins MT, Riminucci M, Banco P. Fibrous dysplasia. In: Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th ed. Washington, D.C.: American Society for Bone and Mineral Research; 2008. p. 423–7.
Bousson V, Rey-Jouvin C, Laredo JD, Le Merrer M, Martin-Duverneuil N, Feydy A, et al. Fibrous dysplasia and McCune-Albright syndrome: imaging for positive and differential diagnoses, prognosis, and follow-up guidelines. Eur J Radiol. 2014;83:1828–42.
Brown ML, Collier BD Jr, Fogelman I. Bone scintigraphy: part 1. Oncology and infection. J Nucl Med. 1993;34:2236–40.
Love C, Palestro CJ. Radionuclide imaging of inflammation and infection in the acute care setting. Semin Nucl Med. 2013;43:102–13.
Collier BD Jr, Fogelman I, Brown ML. Bone scintigraphy: part 2. Orthopedic bone scanning. J Nucl Med. 1993;34:2241–6.
Van der Wall H, Murray IPC. Bone scintigraphy in trauma. In: Ell PJ, Gambhir SS, editors. Nuclear medicine in clinical diagnosis and treatment. 3rd ed. London: Churchill Livingstone; 2005. p. 709–20.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Tsubaki, F., Kurata, S., Nagata, S. et al. Clinical spectrum and diagnostic pitfalls of multiple abnormal uptakes on bone scintigraphy. Jpn J Radiol 34, 771–778 (2016). https://doi.org/10.1007/s11604-016-0585-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11604-016-0585-8